Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track APRE with free AI briefings, catalyst countdowns, and dilution alerts.

APRE · Aprea Therapeutics, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$37.8M Cash on Hand
32.4mo Cash Runway
Follow APRE by email Get an email when APRE reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about APRE, unsubscribe in one click. Privacy

📣 What APRE Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Eprenetapopt (APR-246) MDS Phase 3 · NCT03745716 Completed
ATR Inhibitor ATRN-119 HPV Positive Oropharyngeal Squamous Cell Carcinoma Phase 1/2 · NCT07578467 Not yet recruiting
Pegylated Liposomal Doxorubicin Hydrochloride Platinum Sensitive Recurrent High-grade Serous Ovarian Cancer With… Phase 1/2 · NCT02098343 Completed
Wee1 Inhibitor APR-1051 Advanced Solid Tumor Phase 1 · NCT06260514 Recruiting
p53 Mutant Reactivator APR-548 MDS Phase 1 · NCT04638309 Terminated

Also used in these trials (approved or third-party drugs, not APRE's own candidates): Azacitidine, Dabrafenib, Decitabine, Venetoclax.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

APRE holds $37.8M in cash and short-term investments (as of Sep 30, 2026) and burns about $3.5M/quarter from operations, an estimated runway of 32.4 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 40 · Elevated

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when APRE files for a raise →

👥 Who Owns APRE

Insiders 5.7% Other 5%+ holders 9% Institutions 85.3% Public and other holders 0%
HolderTypeShares% of sharesAs of
Vestal Point Capital, LP Institution (13G, 5%+) 22,654,832 159.64% 2026-03-31
Squadron Master Fund LP 5%+ holder (13G) 1,271,081 8.96% 2026-03-30
Orin Hirschman Institution (13G, 5%+) 1,186,294 8.36% 2026-03-31
Oren Gilad
President/CEO, Director · +178,618 options
Insider 395,695 2.79% 2026-03-12
Marc Duey
Director · +38,199 options
Insider 259,892 1.83% 2026-06-16
Bernd R. Seizinger
Director · +20,925 options
Insider 48,910 0.34% 2026-06-16
John P. Hamill
SrVP/CFO/Prin Fin & Acct Ofcr · +126,496 options
Insider 43,528 0.31% 2026-03-12
Rifat Pamukcu
Director · +20,925 options
Insider 22,689 0.16% 2026-06-16
John B Iii Henneman
Director · +16,740 options
Insider 13,364 0.09% 2026-06-16
Richard Peters
Director · +268,755 options
Insider 6,254 0.04% 2026-06-16
Michael Grissinger
Director · +16,740 options
Insider 6,024 0.04% 2026-06-16
Gabriela Gruia
Director · +16,740 options
Insider 4,180 0.03% 2026-06-16

Share count 14,191,136 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the largest 13F holders. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full APRE picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for APRE and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.